Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia
Status:
RECRUITING
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
This is a dose-finding study of oral zelenirstat (PCLX-001) in patients with R/R AML. There are two parts to the study: Dose Escalation and Dose Expansion.
Phase:
PHASE1
Details
Lead Sponsor:
Pacylex Pharmaceuticals
Collaborators:
Ozmosis Research Inc. United States Department of Defense